U.S. markets open in 7 hours 55 minutes
  • S&P Futures

    4,479.50
    +5.25 (+0.12%)
     
  • Dow Futures

    34,793.00
    +44.00 (+0.13%)
     
  • Nasdaq Futures

    15,534.50
    +16.75 (+0.11%)
     
  • Russell 2000 Futures

    2,229.60
    +1.70 (+0.08%)
     
  • Crude Oil

    72.45
    -0.16 (-0.22%)
     
  • Gold

    1,760.90
    +4.20 (+0.24%)
     
  • Silver

    22.98
    +0.18 (+0.79%)
     
  • EUR/USD

    1.1774
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.3310
    0.0000 (0.00%)
     
  • Vix

    18.69
    +0.51 (+2.81%)
     
  • GBP/USD

    1.3808
    +0.0012 (+0.09%)
     
  • USD/JPY

    109.8800
    +0.1620 (+0.15%)
     
  • BTC-USD

    48,043.03
    -330.44 (-0.68%)
     
  • CMC Crypto 200

    1,229.32
    -3.97 (-0.32%)
     
  • FTSE 100

    7,027.48
    +10.99 (+0.16%)
     
  • Nikkei 225

    30,483.73
    +160.39 (+0.53%)
     

Hims & Hers Health, Inc. Reports First Quarter 2021 Financial Results

  • Oops!
    Something went wrong.
    Please try again later.
·15 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Q1 2021 revenue grows 74% year-over-year to $52.3 million

Q1 2021 gross margin of 77% compared to 69% in Q1 2020

Exceeds Q1 2021 guidance, raises full year 2021 revenue expectations

Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, today reported financial results for the first quarter ending March 31, 2021.

"Building on our momentum from last year, Hims & Hers kicked off 2021 with a very strong first quarter, delivering robust revenue growth of 74%, gross profit growth of 95%, and ending the quarter with 391,000 subscriptions on our platform, up nearly 80% year-over-year," said Andrew Dudum, CEO and co-founder of Hims & Hers. "We made significant headway on our mission of making the highest quality, personalized healthcare accessible to everyone, and we continued to set ourselves apart in the industry with our unified and fully verticalized front door to care."

Mr. Dudum continued, "It’s our unique ability to anticipate what’s next, to meet our target consumers where they are, and to deliver a beautiful, digital experience that keeps us at the forefront of the transformation of healthcare."

Key Business Metrics
(In Thousands, Except AOV)

Three Months Ended

March 31, 2021

December 31, 2020

September 30, 2020

June 30, 2020

March 31, 2020

AOV

$

74

$

69

$

67

$

58

$

52

Net Orders

687

579

582

572

546

Revenue
(In Thousands, Unaudited)

Three Months Ended

March 31, 2021

December 31, 2020

September 30, 2020

June 30, 2020

March 31, 2020

Online Revenue

$

50,680

$

40,091

$

38,829

$

33,284

$

28,524

Wholesale Revenue

1,634

1,375

2,495

2,620

1,539

Total revenue

$

52,314

$

41,466

$

41,324

$

35,904

$

30,063

Total revenue year-over-year growth

74

%

67

%

91

%

76

%

91

%

  • Revenue was $52.3 million for the first quarter 2021 compared to $30.1 million for the first quarter 2020, an increase of 74% year-over-year.

  • Net loss was $(51.4) million for the first quarter 2021 compared to $(6.0) million for the first quarter 2020. The year-over-year increase in net loss was primarily driven by one-time stock-based compensation and transaction bonus expenses related to the merger with Oaktree Acquisition Corp.

  • Gross margin was 77% for the first quarter 2021 compared to 69% for the first quarter 2020.

  • Adjusted EBITDA was $(8.6) million for the first quarter 2021 compared to $(4.6) million for the first quarter 2020.

A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net loss, its most comparable financial measure under generally accepted accounting principles in the United States ("U.S. GAAP"), has been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA is also included below under the heading "Non-GAAP Financial Measures".

Financial Outlook

Hims & Hers provides guidance based on current market conditions and expectations for revenue and Adjusted EBITDA, which is a non-GAAP financial measure.

For the second quarter 2021, we expect:

  • Revenue to be in the range of $55 million to $57 million.

  • Adjusted EBITDA to be in the range of $(10) million to $(12) million.

For the full year 2021, we expect:

  • Revenue to be in the range of $221 million to $227 million.

  • Adjusted EBITDA to be in the range of $(35) million to $(45) million.

The guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the "Cautionary Note Regarding Forward-Looking Statements" safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

We have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net loss. See "Non-GAAP Financial Measures" for additional important information regarding Adjusted EBITDA.

Conference Call

Hims & Hers will host a conference call to review the first quarter 2021 results on May 18, 2021, at 2:00 p.m. PT. The conference call can be accessed by dialing (833) 900-2256 for U.S. participants and (236) 714-2727 for international participants, and referencing conference ID #8982901. A live audio webcast will be available online at https://investors.forhims.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link.

About Hims & Hers Health, Inc.

Hims & Hers is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to primary care, mental health, sexual health, dermatology, and more. Launched in November 2017, the company also offers thoughtfully created and curated health and wellness products. With products and services available across all 50 states and Washington, D.C., Hims & Hers is able to provide access to quality, convenient and affordable care for all Americans. Hims & Hers was founded by CEO Andrew Dudum, Hilary Coles, Jack Abraham and Joe Spector at venture studio Atomic in San Francisco, California. For more information about Hims & Hers, please visit forhims.com and forhers.com.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes," "estimates," "anticipates," "expects," "intends," "plans," "may," "will," "potential," "projects," "predicts," "continue," or "should," or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, financial and business performance, the underlying assumptions, and statements about events and trends including events and trends that we believe may affect our financial condition, results of operations, short- and long-term business operations and objectives, and financial needs, market acceptance and success of our business model, our ability to expand the scope of our offerings, and our ability to comply with the extensive, complex and evolving regulatory requirements applicable to the healthcare industry. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the "Risk Factors" section of our most recently filed Annual Report on Form 10-K for the year ended December 31, 2020, as amended, and our subsequent filings with the Securities and Exchange Commission (the "Commission").

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our annual report on Form 10-K for the year ended December 31, 2020, as amended and our subsequent filings with the Commission. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.

Key Business Metrics

Average Order Value ("AOV") is defined as Online Revenue divided by Net Orders (each as defined below).

"Net Orders" are defined as the number of online customer orders minus transactions related to refunds, credits, chargebacks, and other negative adjustments. Net Orders represent transactions made on our platform during a defined period of time and exclude revenue recognition adjustments recorded pursuant to U.S. GAAP.

"Online Revenue" represents the sales of products and services on our platform, net of refunds, credits, chargebacks and includes revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve.

"Wholesale Revenue" represents non-prescription product sales to retailers through wholesale purchasing agreements.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In Thousands, Except Share and Per Share Data)

March 31,
2021

December 31,
2020

(Unaudited)

Assets

Current assets:

Cash and cash equivalents

$

88,169

$

27,344

Short-term investments

235,097

72,864

Inventory

4,523

3,543

Prepaid expenses and other current assets

12,407

5,404

Deferred transaction costs

3,929

Total current assets

340,196

113,084

Restricted cash, noncurrent

856

1,006

Other long-term assets

4,848

4,607

Total assets

$

345,900

$

118,697

Liabilities, mezzanine equity, and stockholders’ equity (deficit)

Current liabilities:

Accounts payable

$

13,233

$

8,066

Accrued liabilities

5,823

4,984

Deferred revenue

624

1,272

Warrant liabilities

906

Total current liabilities

19,680

15,228

Warrant liabilities

33,370

Deferred rent, noncurrent

384

381

Total liabilities

53,434

15,609

Commitments and contingencies

Mezzanine equity:

Redeemable convertible preferred stock par value $0.0001, 275,000,000 and 95,997,674 shares authorized and nil and 93,328,118 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively; liquidation preference of nil and $268,452 as of March 31, 2021 and December 31, 2020, respectively

249,962

Total mezzanine equity

249,962

Stockholders’ equity (deficit):

Common stock – Class A shares, par value $0.0001, 2,750,000,000 and 166,696,759 shares authorized and 182,973,780 and 46,025,754 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued, and outstanding as of March 31, 2021; Class F shares, par value $0.0001, 6,941,352 shares authorized, issued, and outstanding as of December 31, 2020

18

Additional paid-in capital

515,216

24,429

Accumulated other comprehensive loss

(72)

(11)

Accumulated deficit

(222,696)

(171,292)

Total stockholders’ equity (deficit)

292,466

(146,874)

Total liabilities, mezzanine equity, and stockholders’ equity (deficit)

$

345,900

$

118,697

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In Thousands, Except Share and Per Share Data, Unaudited)

Three Months Ended

March 31,

2021

2020

Revenue

$

52,314

$

30,063

Cost of revenue

12,067

9,444

Gross profit

40,247

20,619

Gross margin %

77

%

69

%

Operating expenses:(1)

Marketing

26,958

12,773

Selling, general, and administrative

61,698

14,064

Total operating expenses

88,656

26,837

Loss from operations

(48,409)

(6,218)

Other income (expense):

Interest expense

(10)

Other (expense) income, net

(2,905)

230

Loss before provision for income taxes

(51,314)

(5,998)

Provision for income taxes

(90)

(35)

Net loss

(51,404)

(6,033)

Other comprehensive loss

(61)

(42)

Total comprehensive loss

$

(51,465)

$

(6,075)

Net loss per share attributable to common stockholders:

Basic and diluted

$

(0.34)

$

(0.17)

Weighted average shares outstanding:

Basic and diluted

153,080,538

34,610,061

______________

(1)

Includes stock-based compensation expense as follows (in thousands):

Three Months Ended

March 31,

2021

2020

Marketing

$

1,846

$

291

Selling, general, and administrative

32,384

1,113

Total stock-based compensation expense

$

34,230

$

1,404

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In Thousands, Unaudited)

Three Months Ended

March 31,

2021

2020

Operating activities

Net loss

$

(51,404)

$

(6,033)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

394

180

Stock-based compensation

34,230

1,404

Change in fair value of warrant liabilities

2,681

(71)

Warrant expense in connection with Merger

154

Amortization of debt issuance costs

144

84

Noncash other

452

(16)

Changes in operating assets and liabilities:

Inventory

(980)

(2,000)

Prepaid expenses and other current assets

(7,147)

(471)

Other long-term assets

(58)

733

Accounts payable

5,117

674

Accrued liabilities

1,114

199

Deferred revenue

(648)

126

Deferred rent

3

Net cash used in operating activities

(15,948)

(5,191)

Investing activities

Purchases of investments

(172,021)

(17,642)

Maturities of investments

9,500

19,200

Proceeds from sales of investments

6,400

Investment in website development and internal-use software

(740)

(452)

Purchases of property, equipment, and intangible assets

(63)

(273)

Net cash (used in)/provided by investing activities

(163,324)

7,233

Financing activities

Proceeds from issuance of redeemable convertible preferred stock

31,600

Payments for issuance costs of convertible preferred stock

(89)

Pre-closing stock repurchase

(22,027)

Proceeds from issuance of common stock upon Merger

197,686

Proceeds from PIPE

75,000

Payments for transaction costs

(12,794)

Repayment of promissory notes associated with vested and unvested shares

1,193

Proceeds from exercise of Class A common stock warrants

807

Proceeds from exercise of vested and unvested stock options, net of repurchases

80

(18)

Repayments of principal on term loan

(1,158)

Net cash provided by financing activities

239,945

30,335

Foreign currency effect on cash and cash equivalents

2

(9)

Increase in cash, cash equivalents, and restricted cash

60,675

32,368

Cash, cash equivalents, and restricted cash at beginning of the year

28,350

22,797

Cash, cash equivalents, and restricted cash at end of the three-month period

$

89,025

$

55,165

Supplemental disclosures of cash flow information

Cash paid for taxes

$

59

$

69

Cash paid for interest

$

$

8

Noncash investing and financing activities

Recapitalization of redeemable convertible preferred stock from pre-closing stock repurchase

$

125

$

Conversion of redeemable convertible preferred stock to common stock

$

249,837

$

Assumption of Merger warrants liability

$

51,814

$

Exercise of Private Placement Warrants and Public Warrants

$

20,871

$

Reclassification of deferred transaction costs

$

3,929

$

Conversion of Series D preferred stock warrants to Class A common warrants

$

1,160

$

Change in transaction costs payable

$

511

$

Vesting of early exercised stock options

$

54

$

11

Expiration of Class A common stock redemption right

$

$

4,500

Non-GAAP Financial Measures:

In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA, a non-GAAP financial measure. We use Adjusted EBITDA to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA, when taken together with the corresponding U.S. GAAP financial measure, provides meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA to be an important measure because it helps illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA is helpful to our investors as it is a metric used by management in assessing the health of our business and our operating performance.

However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. A reconciliation is provided below for Adjusted EBITDA to net loss, the most directly comparable financial measure stated in accordance with U.S. GAAP. Investors are encouraged to review net loss and the reconciliation of Adjusted EBITDA to net loss, and not to rely on any single financial measure to evaluate our business.

Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. "Adjusted EBITDA" is defined as net loss before depreciation and amortization, provision for income taxes, interest income, interest expense, amortization of debt issuance costs, stock-based compensation, change in fair value of warrant liability, and one-time Merger bonuses and warrant expense.

Net Loss to Adjusted EBITDA Reconciliation

(In Thousands, Unaudited)

Three Months Ended

March 31,

2021

2020

Net loss

$

(51,404)

$

(6,033)

Depreciation and amortization

394

180

Provision for income taxes

90

35

Interest income

(82)

(242)

Interest expense

10

Amortization of debt issuance costs

144

84

Stock-based compensation

34,230

1,404

Change in fair value of warrant liability

2,681

(71)

Merger bonuses

5,219

Warrant expense in connection with Merger

154

Adjusted EBITDA

$

(8,574)

$

(4,633)

View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005234/en/

Contacts

Investor Relations
Bob East or Jordan Kohnstam
Westwicke, an ICR company
HIMS-IR@westwicke.com

Media Relations
Press@forhims.com